Blog of Signaling Pathways

Alexander V. Sirotkin “The role of protein kinases in control of ovarian functions”

2667 views | Sep 13 2011

Control of basic physiological processes including reproduction requires multilevel signaling system, which includes hormones, growth factors and related molecules, their receptors and binding proteins, whose alter expression of target genes via protein kinases (PKs) and transcription factors. These signaling substances can control reproductive processes via production, binding and metabolism of regulators of cell cycle, apoptosis, secretory activity, differentiation and oogenesis. [Read the Full Post]

Boosani “Endogenous angiogenesis inhibitors affecting cell survival pathways”

2433 views | Sep 13 2011

Phosphatidylinositol 3-kinases (PI3 kinases) are a group of enzymes categorized into three different classes, among them class I isoforms are well characterized (Stein, 2001). These kinases are the key enzymes that are vital for cell survival with essential role in several cellular functions such as growth, proliferation, differentiation, motility, and intracellular signaling. PI3 Kinases are activated by tyrosine kinases with Akt being the downstream effector molecule (Hennessy et al., 2005). [Read the Full Post]

Novel CDK2 Inhibitors as Anti-Tumor Agents

2420 views | Sep 09 2011

Conventional anti-cancer drugs have mainly focused on targeting DNA synthesis and cell division.n order to avoid these adverse effects, investigators begin to develop a new class of anti-cancer agents, and signal transduction or secondary message inhibitors is one of the successful research findings. [Read the Full Post]

HDACs, play important roles in kidney development

5458 views | Sep 08 2011

Histone deacetylases (HDACs) regulate fundamental biological processes such as cellular proliferation, differentiation, and survival via genomic and non-genomic effects. Some data suggest that HDACs may play a important role in kidney development. [Read the Full Post]

p38 MAPK inhibitor, FR167653, a potent therapy against PTHrP-induced osteoclastogenesis and bone resorption-related diseases

3113 views | Sep 07 2011

Study on mechanism indecates that PTHrP stimulates osteoclastogenesis by increasing receptor activator of NF-kB ligand (RANKL) expression. p38 MAPK is required for osteoclast differentiation. This implies the existence of relationship between p38 MAPK and PTHrP in osteoclastogenesis. [Read the Full Post]

FGFs and the downstream signaling involve in tissue regeneration

4084 views | Sep 06 2011

FGFs have the biological activity of inducing cell proliferation, migration, differentiation, and angiogenesis. As one of the critical components in tissue regeneration, fibroblast growth factors (FGFs) shown the potential effects on the repair and regeneration of tissues. [Read the Full Post]

PI3K/Akt inhibition modulates multidrug resistance

4483 views | Sep 05 2011

Multidrug resistance (MDR), characterized by cancer cell resistance to multiple chemotherapeutic drugs, is a major clinical obstacle in the treatment of hematological malignancies. And many investigators have comfirmed that the PI3K/Akt pathway is associated with chemoresistance in cancer cells. [Read the Full Post]

Li, C., S. Chi, et al. (2011). "Hedgehog signaling in skin cancers." Cell Signal 23(8): 1235-1243.

2966 views | Aug 20 2011

This article introduces the relationship between hedgehog signal transduction and cancer including Skin cancers linked to aberrant hedgehog pathway activity, models of Hh pathway activity in cancer and implications for therapy, and inhibitors and modulators of Hh pathway and their application in skin cancers. [Read the Full Post]

Shaw, A. T. and B. Solomon (2011). "Targeting anaplastic lymphoma kinase in lung cancer." Clin Cancer Res 17(8): 2081-2086.

3698 views | Aug 19 2011

This article reviews the ALK pathway and the Clinical–Translational Advances of different ALK inhibitors. [Read the Full Post]

Kong, X., Y. Shen, et al. (2011). "Emerging roles of DNA-PK besides DNA repair." Cell Signal 23(8): 1273-1280.

4617 views | Aug 19 2011

This article reviews the role of DNA-PK from two aspects. It not only introduces the regulation of DNA-PK activity and the roles of DNA-PK in non-homologous end-joining (NHEJ) repair and homologous recombinant (HR) repair, but also introduces the involvement of DNA-PK in the inflammatory response, in metabolic gene regulation, and in the homeostasis of cell proliferation as well. [Read the Full Post]

Brinkmann, V. (2007). "Sphingosine 1-phosphate receptors in health and disease: mechanistic insights from gene deletion studies and reverse pharmacology." Pharmacol Ther 115(1): 84-105.

3192 views | Jul 22 2011

This article reviews S1P receptor subtypes and associated signaling pathways. The relationship between S1P receptors and different diseases is proved in the article. [Read the Full Post]

Huang, H., A. Bhat, et al. (2010). "Targeting the ANGPT-TIE2 pathway in malignancy." Nat Rev Cancer 10(8): 575-585.

3213 views | Jul 20 2011

This article which is published in Nature review cancer introduce the role of Tie2 in signal transduction such as angiogenesis. It also concludes the inhibitors of Tie2 kinase in cancer therapeutics. [Read the Full Post]

Chiarle, R., C. Voena, et al. (2008). "The anaplastic lymphoma kinase in the pathogenesis of cancer." Nat Rev Cancer 8(1): 11-23.

4117 views | Jul 19 2011

This review which was published in Nature Reviews Cancer concludes the pathways which ALK is involved in and targets that ALK is related to. The content also includes ALK as a therapeutic target in cancer. [Read the Full Post]

Rosse, C., M. Linch, et al. (2010). "PKC and the control of localized signal dynamics." Nat Rev Mol Cell Biol 11(2): 103-112.

4440 views | Jul 19 2011

This review which was published in Nature review summary the role of PKC in different pathways and show the importance of PKCs in controlling spatial resolution in signaling processes using the MET and STAT3 example. [Read the Full Post]

Mumenthaler, S. M., P. Y. Ng, et al. (2009). "Pharmacologic inhibition of Pim kinases alters prostate cancer cell growth and resensitizes chemoresistant cells to taxanes." Mol Cancer Ther 8(10): 2882-2893.

4471 views | Jul 17 2011

These findings support the idea that inhibiting Pim kinases, in combination with a chemotherapeutic agent, could play an important role in prostate cancer treatment by targeting the clinical problem of chemoresistance. [Read the Full Post]

Wong, K. K., J. A. Engelman, et al. (2010). "Targeting the PI3K signaling pathway in cancer." Curr Opin Genet Dev 20(1): 87-90.

2271 views | Jul 16 2011

This is a short review which gives a brief introduction of PI3K and PI3K inhibitors related to cancer research. [Read the Full Post]

Dietrich, J., V. Gokhale, et al. (2010). "Application of a novel [3+2] cycloaddition reaction to prepare substituted imidazoles and their use in the design of potent DFG-out allosteric B-Raf inhibitors." Bioorg Med Chem 18(1): 292-304.

2575 views | Jul 15 2011

An article about drug discovery of b-raf inhibitor design and molecular modeling. [Read the Full Post]

Munoz, L. and A. J. Ammit (2010). "Targeting p38 MAPK pathway for the treatment of Alzheimer

2578 views | Jul 14 2011

This is an introduction of the relationship between p38 MAPK and Alzheimer's disease because p38 MAPK plays an important role in Alzheimer's disease. It also list the p38 MAPK inhibitors Alzheimer's disease patients could benefit from. [Read the Full Post]

Yin, L., O. C. Velazquez, et al. (2010). "Notch signaling: emerging molecular targets for cancer therapy." Biochem Pharmacol 80(5): 690-701.

5100 views | Jul 13 2011

This article is a review which give a presentation of Notch signal pathway and how the researchers target Notch signal pathway for a cancer therapy. [Read the Full Post]

Wong, K. K. (2009). "Recent developments in anti-cancer agents targeting the Ras/Raf/ MEK/ERK pathway." Recent Pat Anticancer Drug Discov 4(1): 28-35.

2291 views | Jul 12 2011

Give an introduction of inhibitors targeting the Ras/Raf/ MEK/ERK pathway. This article summaries the current and future development of anti-cancer drugs or inhibitors of Ras/Raf/ MEK/ERK pathway and the difference between those drugs or inhibitors. [Read the Full Post]